GlassScriptPhysician profile
Lilian S Chuang
NPI 1326068354
$7,977.76
in general payments reported to CMS, 2019-2025
28 companies · $651 in 2025
The $651 reported for 2025 was more than what 96% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,931 · 2020: $551 · 2021: $740 · 2022: $1,419 · 2023: $1,127 · 2024: $560 · 2025: $651.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,337.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,337.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $1,564.63 | 2019-2025 | Vemlidy |
| Bayer Healthcare Pharmaceuticals INC. | $1,065.39 | 2020-2025 | |
| Incyte Corporation | $1,064.48 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
| Pfizer INC. | $502.23 | 2019-2024 | |
| Esperion Therapeutics, INC. | $374.98 | 2022-2023 | Nexletol, Nexlizet |
| Amgen INC. | $367.80 | 2019-2022 | |
| Abbvie INC. | $343.53 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $327.70 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $292.77 | 2021-2023 | Austedo Xr |
| Amarin Pharma, INC. | $283.04 | 2019 | |
| Janssen Pharmaceuticals, INC | $245.41 | 2019 | |
| Portola Pharmaceuticals, LLC | $221.48 | 2019 | |
| Novo Nordisk INC | $218.87 | 2019-2021 | |
| Cranial Technologies, INC | $209.70 | 2021-2025 | Doc Band |
| Merck Sharp & Dohme LLC | $154.53 | 2019-2025 | Vaxelis, Gardasil 9, Capvaxive |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $126.74 | 2020-2023 | Bexsero, Rotarix, Pediarix |
| Mirati Therapeutics, INC. | $124.89 | 2023 | Krazati |
| Lilly USA, LLC | $120.36 | 2019-2023 | Jardiance |
| Eisai INC. | $118.70 | 2019 | |
| Alk-Abello, INC | $68.53 | 2023-2024 | Grastek, Ragwitek, Odactra |
| Radius Health, INC. | $35.00 | 2019 | |
| Daiichi Sankyo INC. | $25.71 | 2022 | |
| Clovis Oncology, INC. | $24.22 | 2020 | |
| Global Blood Therapeutics, INC. | $22.34 | 2021 | |
| Taiho Oncology, INC. | $21.92 | 2022 | |
| Sanofi Pasteur INC. | $19.16 | 2023 | |
| Dova Pharmaceuticals | $18.86 | 2020 | |
| Seqirus USA INC | $14.79 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lilian Chuang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.